• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BLFS

    BioLife Solutions Inc.

    Subscribe to $BLFS
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

    IPO Year:

    Exchange: NASDAQ

    Website: biolifesolutions.com

    Recent Analyst Ratings for BioLife Solutions Inc.

    DatePrice TargetRatingAnalyst
    9/30/2024$29.00Buy
    H.C. Wainwright
    4/4/2024$22.00Buy
    Jefferies
    7/11/2023$29.00Buy
    Craig Hallum
    4/25/2022$28.00Perform → Outperform
    Oppenheimer
    10/19/2021$61.00Buy
    B. Riley Securities
    10/15/2021$64.00Outperform
    Cowen
    8/13/2021$50.00 → $60.00Overweight
    Keybanc
    See more ratings

    BioLife Solutions Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioLife Solutions Updates Earnings Call Information

      BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally. About BioLife Solutions BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our exper

      5/8/25 4:32:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports First Quarter 2025 Financial Results

      Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

      5/8/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati

      4/30/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

      Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens BioLife's position a

      4/7/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

      BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an

      3/18/25 8:30:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results

      Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue for the fourth quarter Expects 2025 Cell Processing revenue of $86.5 to $89.0 million, up 18% to 21% over 2024 and total revenue of $95.5 to $99.0 million, up 16% to 20% over 2024 Conference call begins at 8:00 a.m. Eastern time today  BOTHELL, Wash., March 3, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife"

      3/3/25 7:00:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025

      BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relations page of

      2/20/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

      Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations. Roderick de Greef, Chairman and CEO, commen

      1/13/25 8:30:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary

      Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. "We have now completed the divestiture of all our freezer and related businesses, which began with the sale of Global Cooling

      11/14/24 4:05:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by BioLife Solutions Inc.

      10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      5/8/25 4:20:40 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      5/8/25 4:10:31 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.

      10-K/A - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      4/8/25 4:34:04 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      3/24/25 4:49:46 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-K filed by BioLife Solutions Inc.

      10-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      3/3/25 5:20:44 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      3/3/25 8:00:20 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      1/13/25 8:40:41 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      12/20/24 4:31:25 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      11/20/24 4:39:20 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by BioLife Solutions Inc.

      10-Q - BIOLIFE SOLUTIONS INC (0000834365) (Filer)

      11/12/24 4:22:07 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. Financials

    Live finance-specific insights

    See more
    • BioLife Solutions Reports First Quarter 2025 Financial Results

      Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2025. Roderi

      5/8/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      BOTHELL, Wash., April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relati

      4/30/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company

      Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens BioLife's position a

      4/7/25 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results

      Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18% of total revenue for the fourth quarter Expects 2025 Cell Processing revenue of $86.5 to $89.0 million, up 18% to 21% over 2024 and total revenue of $95.5 to $99.0 million, up 16% to 20% over 2024 Conference call begins at 8:00 a.m. Eastern time today  BOTHELL, Wash., March 3, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife"

      3/3/25 7:00:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025

      BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast, log onto the Investor Relations page of

      2/20/25 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary

      Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. "We have now completed the divestiture of all our freezer and related businesses, which began with the sale of Global Cooling

      11/14/24 4:05:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports Third Quarter 2024 Financial Results

      Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services fo

      11/12/24 4:05:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary

      Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approximately $10.4 million in revenue for the six months ended June 30, 2024.

      11/12/24 8:05:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024

      BOTHELL, Wash., Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update. To access the webcast

      10/31/24 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Reports Second Quarter 2024 Financial Results

      Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader bio

      8/8/24 4:03:00 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Partners Master Fund, L.P. bought $10,374,976 worth of shares (927,165 units at $11.19) (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      10/23/23 5:42:32 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on BioLife Solutions with a new price target

      H.C. Wainwright initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

      9/30/24 7:39:39 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on BioLife Solutions with a new price target

      Jefferies initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $22.00

      4/4/24 7:31:02 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Craig Hallum initiated coverage on BioLife Solutions with a new price target

      Craig Hallum initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $29.00

      7/11/23 8:52:08 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BioLife Solutions from Perform to Outperform and set a new price target of $28.00

      4/25/22 9:02:24 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities initiated coverage on BioLife Solutions with a new price target

      B. Riley Securities initiated coverage of BioLife Solutions with a rating of Buy and set a new price target of $61.00

      10/19/21 8:28:03 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cowen resumed coverage on BioLife Solutions with a new price target

      Cowen resumed coverage of BioLife Solutions with a rating of Outperform and set a new price target of $64.00

      10/15/21 7:17:11 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Keybanc reiterated coverage on BioLife Solutions with a new price target

      Keybanc reiterated coverage of BioLife Solutions with a rating of Overweight and set a new price target of $60.00 from $50.00 previously

      8/13/21 4:55:54 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions downgraded by The Benchmark Company

      The Benchmark Company downgraded BioLife Solutions from Buy to Hold

      5/14/21 7:48:29 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions downgraded by Benchmark

      Benchmark downgraded BioLife Solutions from Buy to Hold

      5/14/21 7:18:27 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions upgraded by Benchmark with a new price target

      Benchmark upgraded BioLife Solutions from Hold to Buy and set a new price target of $54.00

      3/23/21 7:31:39 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. Leadership Updates

    Live Leadership Updates

    See more
    • BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair

      BOTHELL, Wash., March 18, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami, who will remain a company director and member of the audit committee. "Cathy is a highly qualified financial professional with substantial expertise in audits, risk an

      3/18/25 8:30:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

      Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.

      8/25/22 8:03:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioLife Solutions Appoints Joydeep Goswami, MBA, PhD to Board of Directors

      BOTHELL, Wash., Sept. 20, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, will join its board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions. Mr. Goswami replaces Andrew Hinson, who has retired from the board. Mik

      9/20/21 8:00:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors

      BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company's chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen has over 40 years' experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen, an accredited public company director, currently serves as the CEO and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX). In addition, two other accredited public company directors and experienced life science execu

      7/21/21 7:30:00 AM ET
      $AXNX
      $BLFS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • BioLife Solutions Appoints Two New Independent Board Directors

      BOTHELL, Wash., April 6, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately.    Mike Rice, BioLife CEO, commented, "We are very pleased to welcome Amy and Rachel as new independent directors to BioLife's board. They join BioLife at an exciting time. The addition of these directors complements our existing bo

      4/6/21 8:00:00 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      2/13/24 5:00:45 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      1/24/24 4:16:40 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by BioLife Solutions Inc. (Amendment)

      SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      10/24/23 4:29:23 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioLife Solutions Inc.

      SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      9/26/23 4:26:01 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      2/9/23 11:12:40 AM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioLife Solutions Inc. (Amendment)

      SC 13G/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      1/11/23 4:20:31 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioLife Solutions Inc.

      SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      7/8/22 4:56:55 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioLife Solutions Inc.

      SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      6/22/22 4:37:40 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioLife Solutions Inc.

      SC 13G - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      2/9/22 3:33:28 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by BioLife Solutions, Inc. (Amendment)

      SC 13D/A - BIOLIFE SOLUTIONS INC (0000834365) (Subject)

      10/29/21 8:00:18 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    BioLife Solutions Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Large owner Casdin Partners Master Fund, L.P.

      4/A - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/29/25 9:57:30 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Wichterman Troy sold $18,743 worth of shares (932 units at $20.11), decreasing direct ownership by 0.49% to 188,310 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:43 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EVP & Chief Scientific Officer Mathew Aby J. sold $11,443 worth of shares (569 units at $20.11), decreasing direct ownership by 0.18% to 309,007 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:33 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Human Resources Officer Aebersold Sarah sold $4,223 worth of shares (210 units at $20.11), decreasing direct ownership by 0.26% to 79,884 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:23 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Marketing Officer Berard Todd sold $6,516 worth of shares (324 units at $20.11), decreasing direct ownership by 0.24% to 135,632 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:13 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Quality and Operations Foster Karen A. sold $5,751 worth of shares (286 units at $20.11), decreasing direct ownership by 0.15% to 195,567 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/11/25 5:49:02 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Casdin Partners Master Fund, L.P. acquired 27,994 shares (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/9/25 5:08:30 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Human Resources Officer Aebersold Sarah sold $130,771 worth of shares (5,771 units at $22.66), decreasing direct ownership by 7% to 80,094 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/3/25 5:48:43 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Marketing Officer Berard Todd sold $201,719 worth of shares (8,902 units at $22.66), decreasing direct ownership by 6% to 135,956 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/3/25 5:48:33 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Wichterman Troy sold $582,067 worth of shares (25,687 units at $22.66), decreasing direct ownership by 12% to 189,242 units (SEC Form 4)

      4 - BIOLIFE SOLUTIONS INC (0000834365) (Issuer)

      4/3/25 5:48:22 PM ET
      $BLFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care